Pesquisar
Verona Pharma PLC
VRNAAdicionar à lista de desejos
106.910USD
0.0000.00%
Fechamento 06/18, 16:00（ET）Cotações atrasadas em 15 min
73.55BValor de mercado
PerdaP/L TTM
Mais detalhes de Verona Pharma PLC Empresa
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Informações de Verona Pharma PLC
Código da empresaVRNA
Nome da EmpresaVerona Pharma PLC
Data de listagemMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Número de funcionários209
Tipo de títulosDepository Receipt
Fim do ano fiscalMar 30
EndereçoRiverside
CidadeLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Telefone442032834200
Sitehttps://www.veronapharma.com/
Código da empresaVRNA
Data de listagemMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Executivos da empresa Verona Pharma PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+0.66%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Verona Pharma PLC?
Os cinco principais acionistas de Verona Pharma PLC são: Mr. Andrew Fisher
Quantas instituições possuem ações da Verona Pharma PLC (VRNA)?
Em 2025Q3, 467 instituições possuíam ações da Verona Pharma PLC, com valor de mercado aproximado de 76.61M, representando 88.88% do total de ações. Em comparação com 2025Q2, a participação institucional aumentou em -7116945.00.
